BOSTON (TheStreet) -- A calendar of important, potentially stock-moving biotech events for April:

April 7

The U.S. Food and Drug Administration convenes an advisory panel to discuss

Forest Labs'


Daxas for chronic obstruction pulmonary disease. The FDA's briefing documents should be posted to the agency's web site on April 5.

April 8


(CELG) - Get Report

analyst/investor day.

Lexicon Pharmaceuticals

(LXRX) - Get Report

analyst/investor day.

April 9

Cell Therapeutics

(CTIC) - Get Report

annual shareholders meeting.

April 10-17

American Academy of Neurology annual meeting. Data presentations expected from


( GENZ),

Acadia Pharmaceuticals

(ACAD) - Get Report


Acorda Therapeutics

(ACOR) - Get Report

, among others.

April 13-17

AMAG Pharmaceuticals

(AMAG) - Get Report

presents Feraheme data at National Kidney Foundation meeting.

April 14-18

European Association for the Study of the Liver (EASL) annual meeting. Hepatitis C data expected from

Vertex Pharmaceuticals

(VRTX) - Get Report


Idenix Pharmaceuticals



TST Recommends





( ANDS), among others.

April 17-21

American Association for Cancer Research annual meeting. Data presentations expected from

Cyclacel Pharmaceuticals

(CYCC) - Get Report





Peregrine Pharmaceuticals


, among others.

April 18

FDA approval decision date for

OSI Pharmaceuticals'

( OSIP) Tarceva in first-line non-small cell lung cancer.

April 22

FDA convenes advisory panel to review

Acura Pharmaceuticals'


abuse-resistant pain drug Acurox.

April 23

FDA approval decision date for Cell Therapeutics' pixantrone for non-Hodgkin's lymphoma.

April 30

FDA approval decision date for



pain drug Vimovo.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on



Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.